PDF DatasheetHuman Anti-Podoplanin Antibody Product Attributes
Podoplanin Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-PDPN antibody staining is expected to be primarily localized to the vesicles.
Observed Antibody Staining Data By Tissue Type:
Variations in Podoplanin antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in myoepithelial cells in the breast and endothelial cells in the colon. More moderate antibody staining intensity was present in myoepithelial cells in the breast and endothelial cells in the colon. Low, but measureable presence of Podoplanin could be seen inrespiratory epithelial cells in the bronchus, endothelial cells in the cerebral cortex, peripheral nerve/ganglion in colon, squamous epithelial cells in the esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, follicle cells in the ovary, ovarian stroma cells in the ovary, chondrocytes in mesenchymal tissue, peripheral nerve in mesenchymal tissue and squamous epithelial cells in the vagina. We were unable to detect Podoplanin in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Podoplanin expression as measured by anti-Podoplanin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | ++ | – | – | – | – | – | – | – | – | – | – | – | + | – | ++ | – | – |
| PDPN Variability | + | ++ | ++ | ++ | ++ | ++ | ++ | + | + | ++ | + | + | + | + | + | ++ | + | ++ | + | ++ |
| Podoplanin General Information | |
|---|---|
| Alternate Names | |
| Podoplanin, PDPN | |
| Molecular Weight | |
| 38-43kDa | |
| Chromosomal Location | |
| 1p36.21 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | PDPN |
| Entrez Gene ID | 10630 |
| Ensemble Gene ID | ENSG00000162493 |
| RefSeq Protein Accession(s) | NP_938203, NP_001006625, NP_001006626, NP_006465, XP_006710358 |
| RefSeq mRNA Accession(s) | XM_006710295, NM_001006624, NM_198389, NM_006474, NM_001006625 |
| RefSeq Genomic Accession(s) | NC_018912, NC_000001 |
| UniProt ID(s) | Q86YL7 |
| UniGene ID(s) | Q86YL7 |
| HGNC ID(s) | 29602 |
| Cosmic ID(s) | PDPN |
| KEGG Gene ID(s) | hsa:10630 |
| PharmGKB ID(s) | PA142671187 |
| General Description of Podoplanin. | |
| This MAb recognizes a muco-protein of 38-43kDa, which is identified Podoplanin (PDPN). It localizes in stromal cells of peripheral lymphoid tissue and thymic epithelial cells. As a regulator of the lymphatic endothelium, podoplanin probably plays a role in maintaining the unique shape of podocytes. It is selectively expressed in lymphatic endothelium as well as lymphoangiomas, Kaposi sarcomas, and in a subset of angiosarcomas with probable lymphatic differentiation. Recent studies have also shown podoplanin to be a highly sensitive and relatively specific marker for epithelioid mesothelioma. Therefore, it can be used in a panel to distinguish mesotheliomas or mesothelial cells from pulmonary carcinomas. | |
There are no reviews yet.